Psoriasis Clinical Trials in New York

Showing 101-120 of 183 trials

Trial of CF101 to Treat Patients With Psoriasis

NCT01265667

Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.

Plaque Psoriasis

Can-Fite BioPharma293 participantsStarted Jul 2011

New York, New York, United States • Pleven, Bulgaria • Sofia, Bulgaria +15 more locations

COMPLETEDPhase 3< 1 mile

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

NCT02899962

A phase 3 trial comparing the efficacy and safety of LEO 90100 aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance therapy in subjects with psoriasis vulgaris. A 12-month, international, multi-centre, randomised, vehicle controlled, double-blind, 2-arm, parallel group trial.

Psoriasis Vulgaris

LEO Pharma722 participantsStarted Feb 2017

Fremont, California, United States • Santa Monica, California, United States • Denver, Colorado, United States +55 more locations

Trial of CF101 to Treat Patients With Psoriasis

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Psoriasis Trials in Other Cities

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

Duobrii in Combination With Biologics

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

AMG 827 in Subjects With Psoriatic Arthritis

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis

Other Conditions in New York